Core Insights - ResMed Inc reported better-than-expected earnings for Q2, with earnings of $2.55 per share, surpassing the analyst consensus estimate of $2.46 per share [1] - The company achieved quarterly sales of $1.348 billion, exceeding the analyst consensus estimate of $1.321 billion [1] Company Performance - The strong finish to fiscal year 2025 is attributed to robust global demand for ResMed's sleep and breathing health devices and the expansion of its digital health ecosystem, as stated by the Chairman and CEO, Mick Farrell [2] - Following the earnings announcement, ResMed shares increased by 2.1%, trading at $277.70 [2] Analyst Ratings and Price Targets - Piper Sandler maintained a Neutral rating and raised the price target from $248 to $270 [7] - Keybanc maintained an Overweight rating and increased the price target from $274 to $298 [7] - UBS maintained a Buy rating and boosted the price target from $285 to $325 [7] - RBC Capital maintained an Outperform rating and raised the price target from $294 to $300 [7] - Stifel maintained a Hold rating and increased the price target from $240 to $270 [7] - Mizuho maintained an Outperform rating and raised the price target from $270 to $290 [7]